Le Lézard
Classified in: Health, Business
Subject: LIC

Dompé and The Farmamondo Group: Exclusive Agreement to Distribute Oxervatetm in Russia and Other CIS Countries


MILAN, Nov. 26, 2020 /PRNewswire/ -- Dompé farmaceutici Spa and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner to make their innovative product Oxervatetm (Cenegermin) available for patients affected by Neurotrophic Keratitis (NK) in Russia and other CIS countries.

Dompe_Logo

The agreement appoints FarmaMondo as the exclusive provider of access for those NK patients with unmet need through a Named Patient Managed Access Program. The possibility to access the therapy shall bring great hope for NK patients and their families in the region

"We are pleased to be working with FarmaMondo to deliver this innovative treatment to patients with a serious unmet medical need. We believe expanding the distribution of Oxervate will dramatically improve the life of many now living with a highly debilitating disease," said Eriona Gjinukaj, Chief Operating Officer of Dompé.

About Neurotrophic Keratitis
NK is a rare, degenerative disease of the cornea which results in persistent epithelial defects, corneal ulcers, melting, perforation and vision loss. It is an orphan disease with an estimated prevalence of less than 5/10,000 individuals, and previous treatment options had been limited to symptomatic treatments which do not target the underlying disease pathology.

About Oxervate:
Oxervate (cenegermin) is a first-in-class treatment for neurotrophic keratitis, with a mechanism of action that targets the root pathology of the disease. It is the first-ever application of a human nerve growth factor as drug or treatment and is the first-ever topical biologic medication approved in ophthalmology.

About Farmamondo
FarmaMondo is a Swiss-headquartered pharmaceutical group focused on providing market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to facilitate patient's access to medicines across the unlicensed and licensed product lifecycle phases. FarmaMondo support biopharmaceutical companies in their mission to extend greater access for their medicines by ethically supplying product to patients in markets where it has not been commercially launched yet. For more information about FarmaMondo please visit www.farmamondo.com.

About Dompé
Dompé is an Italian bi-pharmaceutical company that focuses on innovation, with a long tradition in the field of personal wellness that goes hand in hand with a commitment to research and development to meet the unsatisfied therapeutic needs of patients. Dompé, based in Milan with a presence in the United States, Europe and China, focuses specifically in the field of rare diseases within its biotechnology unit, in recent years moving into the area of ophthalmology. For more information, visit www.dompe.com.

Logo - https://mma.prnewswire.com/media/1190715/Dompe_Logo.jpg

 


These press releases may also interest you

at 18:56
Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:...

at 18:30
Striking Teamsters at pharmaceutical giant Cencora (formerly known as AmerisourceBergen) rallied today outside the company's Sacramento distribution center. The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since...

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....

at 17:58
More than 200 workers at American Medical Response (AMR) in Springfield and Greenfield have voted overwhelmingly to join Teamsters Local 404....

at 17:54
The American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, is celebrating National Doctors Day by highlighting three top kidney medical experts and authors known for their...

at 17:20
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...



News published on and distributed by: